Loading...
AXDX.Q logo

Accelerate Diagnostics, Inc.OTCPK:AXDX.Q Stock Report

Market Cap US$25.0
Share Price
n/a
1Y-100.0%
7D0%
1D0%
Portfolio Value
​
View

Accelerate Diagnostics, Inc.

OTCPK:AXDX.Q Stock Report

Market Cap: US$25.0

Accelerate Diagnostics (AXDX.Q) Stock Overview

An in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. More details

AXDX.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Rewards

Earnings have grown 10.3% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Negative shareholders equity

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($25)


AXDX.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW496,346 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
496,346 investors already sharing narratives
View all narratives

Accelerate Diagnostics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Accelerate Diagnostics
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$2.09
52 Week LowUS$0.000001
Beta-0.23
1 Month Change-99.99%
3 Month Change-99.99%
1 Year Change-100.00%
3 Year Change-100.00%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Analysis Article • Apr 17

Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher

Accelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders are no doubt pleased to see that the share price has bounced...
Seeking Alpha • Aug 30

Accelerate Diagnostics spikes as Chief Technology Officer raises stake

The shares of in vitro diagnostics firm Accelerate Diagnostics, Inc. (NASDAQ:AXDX) jumped Tuesday after its Chief Technology Officer Larry Michael Mertz announced the purchase of 50K company shares. According to a regulatory filing today, Mr. Mertz bought $80K worth of AXDX shares at $1.60 apiece on Aug. 30, raising his stake by ~13%. The latest transaction comes a week after Mr. Mertz added ~51.7K AXDX shares, increasing his ownership in the company by ~16%. Mertz has served as the Senior Vice President, Head of R&D at AXDX since May 2021. The insider trading comes after the company recently announced a public offering of 17.5M shares of common stock at $2.00 per share. The share issuance was expected to raise $35M in gross proceeds for general corporate purposes and commercialization efforts.
Analysis Article • Aug 20

Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Accelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Aug 15

Accelerate Diagnostics jumps 14% after beating Q2 estimates

Vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, Accelerate Diagnostics (NASDAQ:AXDX) reported Q2 sales of $3.9M, a 39% jump from last year; beats consensus by $0.76M. Growth was driven by increases in both capital and recurring revenues Gross margin was 28% vs. 38%; decline in gross margins resulted from inflation to manufacturing costs and other factors. SG&A costs were $11.5M, vs. $12.9M from prior year. R&D costs were $7.6M, vs. $5.7M. Signed an agreement in August 2022 to exchange $50M of convertible debt due March 2023 for a term loan due in five years with no cash interest due during the term. "In addition to a solid quarter, I am pleased to announce that we will be joining forces with Becton Dickinson to commercialize our products globally. Our global commercial partnership with BD comes at a time when the hospital selling environment is improving, we are firing on all cylinders in R&D and are taking meaningful steps to improve our balance sheet.  These are exciting times for our company." commented Jack Phillips, CEO. Total cash, investments, and cash equivalents of $36.8M. GAAP EPS of -$0.23 beats consensus by $0.05. Quant rating of Hold 3.00 with lowest factor grades to profitability. Sell-side analyst give the stock a Hold rating with 3.00 score and an average price target of $1.00 Previously (Aug. 15): Accelerate Diagnostics GAAP EPS of -$0.23 beats by $0.05, revenue of $3.86M beats by $0.76M
Analysis Article • Mar 15

Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022

Market forces rained on the parade of Accelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders today, when the...
Seeking Alpha • Jan 04

Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022

Both Accelerate Diagnostics and T2 Biosystems have developed promising technology related to the rapid detection of bacterial infections, notably sepsis. Sepsis is responsible for 270,000 deaths in the U.S. annually, making it hospitals' most deadly killer. It is a $62 billion-per-annum burden on the U.S. health system. Both T2 and Accelerate had a rough 2021, however, with their share prices respectively falling by more than 60% and 30%. Neither company appears able to persuade hospitals that their technologies offer an optimal solution to the problem to rapid detection and treatment of sepsis. That is a major problem for both and the reason I think both stocks could continue to suffer in 2022. T2 already faces delisting; Accelerate's shares have further to fall.
Seeking Alpha • Sep 07

Accelerate Diagnostics: An Investment Assessment

Today, we take a deeper look at a medical diagnostics firm called Accelerate Diagnostics. Recently, the company launched its AST-focused test kit, successfully concluded its multi-hospital registry study, and continued to advance its commercialization efforts. A full investment analysis is laid out in the paragraphs below.
Analysis Article • Feb 20

Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Analysis Article • Dec 29

Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three Years

It's not possible to invest over long periods without making some bad investments. But really big losses can really...

Shareholder Returns

AXDX.QUS Medical EquipmentUS Market
7D0%2.2%1.6%
1Y-100.0%-19.0%18.6%

Return vs Industry: AXDX.Q underperformed the US Medical Equipment industry which returned 6.2% over the past year.

Return vs Market: AXDX.Q underperformed the US Market which returned 14.4% over the past year.

Price Volatility

Is AXDX.Q's price volatile compared to industry and market?
AXDX.Q volatility
AXDX.Q Average Weekly Movement490,547.5%
Medical Equipment Industry Average Movement8.5%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: AXDX.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: AXDX.Q's weekly volatility has increased from 222174% to 490548% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1982107Jack Phillipsacceleratediagnostics.com

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides Accelerate PhenoTest BC Kit, a test kit for the system, which is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.

Accelerate Diagnostics, Inc. Fundamentals Summary

How do Accelerate Diagnostics's earnings and revenue compare to its market cap?
AXDX.Q fundamental statistics
Market capUS$25.00
Earnings (TTM)-US$50.04m
Revenue (TTM)US$11.70m
0.0x
P/S Ratio
0.0x
P/E Ratio

Is AXDX.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AXDX.Q income statement (TTM)
RevenueUS$11.70m
Cost of RevenueUS$8.99m
Gross ProfitUS$2.70m
Other ExpensesUS$52.75m
Earnings-US$50.04m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.99
Gross Margin23.12%
Net Profit Margin-427.81%
Debt/Equity Ratio-113.0%

How did AXDX.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/22 03:29
End of Day Share Price 2025/08/20 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Accelerate Diagnostics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sean LavinBTIG
Alexander NowakCraig-Hallum Capital Group LLC
Tycho PetersonJ.P. Morgan